Chronicle Journal: Finance

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

82.93 USD -0.22 (-0.26%)
Official Closing Price Updated: 7:56 PM EDT, Sep 25, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,614,900
Open 82.15
Bid (Size) 82.47 (1)
Ask (Size) 82.92 (2)
Prev. Close 83.15
Today's Range 81.80 - 83.24
52wk Range 65.25 - 92.64
Shares Outstanding 2,690,303,898
Dividend Yield 2.32%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
NEXPLANON® Contraceptive Arm Implant Now Available for Use in Canada
From PR Newswire
Merck Joins Groundbreaking Gender and Diversity KPI Alliance
Tags KPI Alliance Gender Equality Partnerships
From 3BL Media: Corporate Social Responsibility, Energy and Health News

Performance

YTD
-9.90%
-9.90%
1 Month
-3.18%
-3.18%
3 Month
+8.95%
+8.95%
6 Month
+7.77%
+7.77%
1 Year
-1.48%
-1.48%

More News

Read More
Investors Are Scrambling To Get Ahead Of The Oncology Drug Market Boom; 1 Company Could Revolutionize The Industry
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer
From Business Wire News Releases
First-Line Treatment With Merck’s KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tum
From Business Wire News Releases
There are four coronavirus vaccines in late-stage studies; here’s how they differ
Tags MRNA UK:AZN FR:SAN
From MarketWatch
LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for Treatment of BRCA1/2 Metastatic Castration-Resistant Prostate Cancer (mCRPC)
From Business Wire News Releases
Here's the Bigger Story About Moderna That You Might Be Missing
Tags MRNA Market News VRTX
From Motley Fool
LYNPARZA® (olaparib) Recommended for Approval in EU by CHMP as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
From Business Wire News Releases
Notable Wednesday Option Activity: ZS, DRI, MRK
Tags Stocks
From Market News Video
LYNPARZA® (olaparib) Reduced the Risk of Death by 31% in BRCA1/2 or ATM-mutated Metastatic Castration-Resistant Prostate Cancer in Phase III Profound Trial
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]